From Risk Factors to Structural Heart Disease: The Role of Inflammation

Heart Failure Clinics

Volumn 8, Issue 1, 2012, Pages 113-123

  Kalogeropoulos, Andreas P ^a   Georgiopoulou, Vasiliki V ^a   Butler, Javed ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Cytokines; Heart failure; Inflammation; Left ventricular dysfunction

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

AGING; ARTERIAL STIFFNESS; CARDIAC PATIENT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDITIS; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIASTOLIC DYSFUNCTION; DIETARY FIBER; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EXERCISE; FAT INTAKE; FIBROSIS; FISH; FRUIT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE FUNCTION; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; NONHUMAN; OBESITY; REPERFUSION INJURY; REVIEW; SEDENTARY LIFESTYLE; SMOKING; VEGETABLE;

ANIMALS; CYTOKINES; DISEASE PROGRESSION; HEART FAILURE; HUMANS; INFLAMMATION; MYOCARDIUM; RISK FACTORS; VENTRICULAR REMODELING;

EID: 82955233194     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.08.002     Document Type: Review

References (93)

1. Khaper N., Bryan S., Dhingra S., et al. Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. Antioxid Redox Signal 2010, 13:1033-1049.
2. Cieslik K.A., Taffet G.E., Carlson S., et al. Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 2011, 50:248-256.
3. Sekiguchi K., Li X., Coker M., et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res 2004, 63:433-442.
4. Sciarretta S., Paneni F., Palano F., et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009, 116:467-477.
5. Felder R.B. Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Exp Physiol 2010, 95:19-25.
6. Hori M., Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009, 81:457-464.
7. Lee J.H., O'Keefe J.H., Bell D., et al. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?. J Am Coll Cardiol 2008, 52:1949-1956.
8. Ndisang J.F. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediators Inflamm 2010, 2010:359732.
9. Dhingra R., Gona P., Nam B.H., et al. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med 2007, 120:1054-1062.
10. Kalogeropoulos A., Georgiopoulou V., Psaty B.M., et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010, 55:2129-2137.
11. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Serum resistin concentrations and risk of new onset heart failure in older persons: the Health, Aging, and Body Composition (Health ABC) study. Arterioscler Thromb Vasc Biol 2009, 29:1144-1149.
12. Frankel D.S., Vasan R.S., D'Agostino R.B.S., et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009, 53:754-762.
13. Engstrom G., Melander O., Hedblad B. Carotid intima-media thickness, systemic inflammation, and incidence of heart failure hospitalizations. Arterioscler Thromb Vasc Biol 2009, 29:1691-1695.
14. Suzuki T., Katz R., Jenny N.S., et al. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2008, 1:242-248.
15. Bahrami H., Bluemke D.A., Kronmal R., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008, 51:1775-1783.
16. Suleiman M., Khatib R., Agmon Y., et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006, 47:962-968.
17. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491.
18. Alam I., Lewis K., Stephens J.W., et al. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 2007, 8:119-127.
19. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
20. Vidt D.G. Inflammation in renal disease. Am J Cardiol 2006, 97:20A-27A.
21. Maestrelli P., Saetta M., Mapp C.E., et al. Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:S76-S80.
22. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu Rev Immunol 2010, 29:415-445.
23. Forsythe L.K., Wallace J.M., Livingstone M.B. Obesity and inflammation: the effects of weight loss. Nutr Res Rev 2008, 21:117-133.
24. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
25. Kasai T., Bradley T.D. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol 2011, 57:119-127.
26. Kasapis C., Thompson P.D. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 2005, 45:1563-1569.
27. O'Connor M.F., Irwin M.R. Links between behavioral factors and inflammation. Clin Pharmacol Ther 2010, 87:479-482.
28. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
29. Helmersson J., Larsson A., Vessby B., et al. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 2005, 181:201-207.
30. Wannamethee S.G., Lowe G.D., Shaper A.G., et al. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005, 26:1765-1773.
31. Fogarty A.W., Lewis S.A., McKeever T.M., et al. Is higher sodium intake associated with elevated systemic inflammation? A population-based study. Am J Clin Nutr 2009, 89:1901-1904.
32. Mickleborough T.D., Lindley M.R., Ray S. Dietary salt, airway inflammation, and diffusion capacity in exercise-induced asthma. Med Sci Sports Exerc 2005, 37:904-914.
33. Forrester D.L., Britton J., Lewis S.A., et al. Impact of adopting low sodium diet on biomarkers of inflammation and coagulation: a randomised controlled trial. J Nephrol 2010, 23:49-54.
34. Nakandakare E.R., Charf A.M., Santos F.C., et al. Dietary salt restriction increases plasma lipoprotein and inflammatory marker concentrations in hypertensive patients. Atherosclerosis 2008, 200:410-416.
35. Singh T., Newman A.B. Inflammatory markers in population studies of aging. Ageing Res Rev 2011, 10(3):319-329.
36. Papanicolaou D.A., Wilder R.L., Manolagas S.C., et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998, 128:127-137.
37. Davison S., Davis S.R. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003, 88:2470-2478.
38. Maggio M., Basaria S., Ceda G.P., et al. The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest 2005, 28:116-119.
39. Nian M., Lee P., Khaper N., et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94:1543-1553.
40. Hedayat M., Mahmoudi M.J., Rose N.R., et al. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010, 15:543-562.
41. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
42. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997, 81:627-635.
43. Yokoyama T., Vaca L., Rossen R.D., et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993, 92:2303-2312.
44. Jozefowicz E., Brisson H., Rozenberg S., et al. Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats. Crit Care Med 2007, 35:856-863.
45. Torre-Amione G., Kapadia S., Lee J., et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92:1487-1493.
46. Kim M., Oh J.K., Sakata S., et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008, 45:270-280.
47. Jiang B., Liao R. The paradoxical role of inflammation in cardiac repair and regeneration. J Cardiovasc Transl Res 2010, 3:410-416.
48. Frantz S., Bauersachs J., Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009, 81:474-481.
49. Sam F., Sawyer D.B., Chang D.L., et al. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol Heart Circ Physiol 2000, 279:H422-H428.
50. Dorn G.W. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 2009, 6:283-291.
51. Suleiman M., Aronson D., Reisner S.A., et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 2003, 115:695-701.
52. Gabriel A.S., Martinsson A., Wretlind B., et al. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med 2004, 15:523-528.
53. Orn S., Manhenke C., Ueland T., et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 2009, 30:1180-1186.
54. Laura P.A., Michela D.R., Silvia M., et al. Pro/anti-inflammatory cytokine imbalance in postischemic left ventricular remodeling. Mediators Inflamm 2010, 2010:974694.
55. Nagai T., Anzai T., Kaneko H., et al. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 2011, 57:208-215.
56. Sun M., Chen M., Dawood F., et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007, 115:1398-1407.
57. Chen Y., Pat B., Zheng J., et al. Tumor necrosis factor-alpha produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload. J Mol Cell Cardiol 2010, 49:70-78.
58. Ulasova E., Gladden J.D., Chen Y., et al. Loss of interstitial collagen causes structural and functional alterations of cardiomyocyte subsarcolemmal mitochondria in acute volume overload. J Mol Cell Cardiol 2011, 50:147-156.
59. Levick S.P., Gardner J.D., Holland M., et al. Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol 2008, 45:56-61.
60. Kadokami T., Frye C., Lemster B., et al. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001, 104:1094-1097.
61. Jobe L.J., Melendez G.C., Levick S.P., et al. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol 2009, 297:H1462-H1468.
62. Kapadia S.R., Yakoob K., Nader S., et al. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000, 36:208-212.
63. Tschope C., Westermann D. Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment. Herz 2009, 34:89-96.
64. Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350:1953-1959.
65. Kruger M., Linke W.A. Titin-based mechanical signalling in normal and failing myocardium. J Mol Cell Cardiol 2009, 46:490-498.
66. Jellis C., Martin J., Narula J., et al. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010, 56:89-97.
67. Matsubara L.S., Matsubara B.B., Okoshi M.P., et al. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats. Can J Physiol Pharmacol 1997, 75:1328-1334.
68. Cleutjens J.P., Creemers E.E. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction. J Card Fail 2002, 8:S344-S348.
69. Kuwahara F., Kai H., Tokuda K., et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106:130-135.
70. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 1999, 147:213-225.
71. Kuwahara F., Kai H., Tokuda K., et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?. Hypertension 2004, 43:739-745.
72. Westermann D., Lindner D., Kasner M., et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011, 4:44-52.
73. Haugen E., Chen J., Wikstrom J., et al. Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats. Int J Cardiol 2007, 115:24-28.
74. Dinh W., Futh R., Nickl W., et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol 2009, 8:58.
75. Kosmala W., Derzhko R., Przewlocka-Kosmala M., et al. Plasma levels of TNF-alpha, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis 2008, 19:375-382.
76. Williams E.S., Shah S.J., Ali S., et al. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail 2008, 10:63-69.
77. Arruda-Olson A.M., Enriquez-Sarano M., Bursi F., et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am J Cardiol 2010, 105:917-921.
78. Mori T., Kai H., Kajimoto H., et al. Enhanced cardiac inflammation and fibrosis in ovariectomized hypertensive rats: a possible mechanism of diastolic dysfunction in postmenopausal women. Hypertens Res 2011, 34(4):496-502.
79. Watts G.F., Marwick T.H. Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance. Clin Sci (Lond) 2003, 105:537-540.
80. Ooi H., Chung W., Biolo A. Arterial stiffness and vascular load in heart failure. Congest Heart Fail 2008, 14:31-36.
81. Kang S., Fan H.M., Li J., et al. Relationship of arterial stiffness and early mild diastolic heart failure in general middle and aged population. Eur Heart J 2010, 31:2799-2807.
82. Heitzer T., Baldus S., von Kodolitsch Y., et al. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005, 25:1174-1179.
83. Lapu-Bula R., Ofili E. From hypertension to heart failure: role of nitric oxide-mediated endothelial dysfunction and emerging insights from myocardial contrast echocardiography. Am J Cardiol 2007, 99:7D-14D.
84. Yasmin McEniery C.M., Wallace S., Mackenzie I.S., et al. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004, 24:969-974.
85. Mahmud A., Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005, 46:1118-1122.
86. Scuteri A., Orru M., Morrell C., et al. Independent and additive effects of cytokine patterns and the metabolic syndrome on arterial aging in the SardiNIA Study. Atherosclerosis 2010, 215(2):459-464.
87. Kobayasi R., Akamine E.H., Davel A.P., et al. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens 2010, 28:2111-2119.
88. Jablonski K.L., Chonchol M., Pierce G.L., et al. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011, 57:63-69.
89. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008, 1:125-133.
90. Kalogeropoulos A., Psaty B.M., Vasan R.S., et al. Validation of the health ABC heart failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail 2010, 3:495-502.
91. Li J., Leschka S., Rutschow S., et al. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur J Pharmacol 2007, 554:60-68.
92. Li S., Zhong S., Zeng K., et al. Blockade of NF-kappaB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats. Basic Res Cardiol 2010, 105:139-150.
93. Gullestad L., Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005, 95:17C-23C. [discussion: 38C-40C].